Ensysce Biosciences, Inc. (ENSC): Revenue
$5.07M
Year ended 2025-12-31
$4.50M
Trailing 12 months to 2026-06-30
+26.2%
3-year compound annual growth
+5.2%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.07M | -2.8% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $5.21M | +133.6% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $2.23M | -11.6% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $2.52M | -28.5% | 2024-03-15, From 2022-01-01 |
| 2021-12-31 | $3.53M | -10.2% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $3.93M | n/a | 2022-03-31, From 2020-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $5.07M | -2.8% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $4.34M | -35.8% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $4.14M | -8.5% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $6.39M | +181.5% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $4.01M | -58.9% |
| Immunome Inc. (IMNM) | 2025-12-31 | $6.94M | -23.2% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $7.14M | -72.5% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $3.55M | -46.2% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $7.25M | n/m |
Compare ENSC, PRPH, CPHI, KRRO side by side · Screen every company in Pharmaceutical Preparations ↗